Strategic Guide to Stability Testing of Biopharmaceutical Combination Products

Combination products—those that integrate a biologic with a device component—represent a growing segment in the pharmaceutical landscape. These include autoinjectors, prefilled syringes (PFS), on-body injectors, and inhalable biologics. Stability studies for such products are inherently complex, requiring simultaneous evaluation of drug integrity and device performance. This tutorial outlines the strategic, technical, and regulatory approaches to designing robust stability programs for biopharmaceutical combination products.

What Are Combination Biologic Products?

A combination product comprises two or more regulated components—typically a drug (biologic) and a device—physically, chemically, or otherwise combined to be used together. Common examples in the biopharma space include:

• Monoclonal antibodies in prefilled syringes or autoinjectors
• Insulin pens and cartridges
• PEGylated biologics in wearable infusion devices
• Implantable devices eluting cytokines or peptides

Why Stability Testing Is Challenging for Combination Products

Unlike standalone drug products, combination products present additional challenges such as:

• Interaction between drug and device materials (e.g., rubber, silicone, adhesives)
• Drug degradation due to extractables and leachables (E&L)
• Impact of storage conditions on mechanical or electronic components
• Need for functionality testing alongside chemical and microbiological testing
• Multiple regulatory jurisdictions (CDER + CDRH for FDA)

A well-designed stability study must address both pharmaceutical and engineering risks across the product’s lifecycle.

Regulatory Guidance on Combination Product Stability

Regulatory agencies have issued specific frameworks for assessing combination product quality:

• FDA 21 CFR Part 4: Applies CGMPs to combination products
• FDA Guidance: Current Good Manufacturing Practice for Combination Products
• ICH Q5C: Stability Testing of Biotech/Biological Products (drug portion)
• ISO 11608 Series: Functional requirements for needle-based injection systems
• USP , , , : Packaging, extractables, and leachables

Both drug and device components must be tested under unified stability protocols with appropriate acceptance criteria.

Step-by-Step Approach to Designing Stability Studies

Step 1: Define the Product Configuration and Use-Case

Start by defining the combination product structure:

• Primary container (e.g., glass syringe, polymer cartridge)
• Device interface (e.g., plunger, needle, auto-injection mechanism)
• Delivery method (manual vs. electronic vs. wearable)

Consider the intended use, number of actuations, and dose delivery per use to inform the stability design.

Step 2: Establish Storage Conditions and Test Timepoints

Use ICH-recommended conditions unless otherwise justified:

• Long-term: 2–8°C for refrigerated products, 25°C/60% RH for ambient
• Accelerated: 40°C/75% RH for up to 6 months

Test timepoints may include 0, 3, 6, 9, 12, 18, and 24 months based on proposed shelf life. Include in-use stability if applicable (e.g., product used multiple times after opening).

Step 3: Evaluate Drug Stability in Final Configuration

Use stability-indicating methods to assess biologic integrity within the device:

• Potency: Bioassays, ELISA
• Purity: CE-SDS, HPLC
• Aggregation: SEC, DLS
• Sub-visible particles: MFI, HIAC
• pH, osmolality, appearance

Test the product in the actual configuration it will be distributed and used (e.g., pre-assembled syringe with needle shield).

Step 4: Conduct Extractables and Leachables Studies

Device materials (elastomers, adhesives, lubricants) may leach into the biologic over time. Conduct E&L testing per USP /:

• Simulate storage and use conditions (thermal, humidity, light)
• Analyze leachables using GC-MS, LC-MS, ICP-MS
• Compare against safety thresholds (e.g., TTC, PDE)

Perform risk-based toxicological evaluation of detected leachables.

Step 5: Test Mechanical Functionality Under Stability Conditions

Device functionality must remain within specification over shelf life. Include tests such as:

• Plunger glide force, break-loose force
• Injection time and dose accuracy
• Needle deployment/retraction mechanisms
• Electronic actuation performance (for digital or wearable devices)

Perform function testing at each timepoint under ICH conditions.

Step 6: Assess Container Closure Integrity (CCI)

Especially critical for sterile injectable products. Use deterministic methods like:

• Vacuum decay
• Helium leak detection
• High-voltage leak detection (HVLD)

Confirm microbial ingress protection across time and storage conditions.

Step 7: Include In-Use Stability (If Applicable)

For products used over multiple doses or requiring reconstitution before use:

• Simulate puncture and dose withdrawal
• Store under recommended in-use conditions (e.g., 2–8°C post-opening)
• Test for potency, sterility, and microbial limits

Packaging Considerations in Combination Products

Materials such as glass, cyclic olefin polymers (COP), and elastomers must be compatible with biologics. Evaluate:

• Adsorption of protein to surfaces
• Silicone oil migration and interaction with active ingredient
• Metal ions from crimp or needle components

Choose container materials based on formulation pH, ionic strength, and protein concentration.

Case Study: Autoinjector Stability for a PEGylated Biologic

A PEGylated interferon biologic was developed in a 1 mL autoinjector system. Stability testing included 0–24 months at 2–8°C and 0–6 months at 40°C. Results showed no potency loss or aggregation. Leachables analysis confirmed sub-threshold levels of cyclic olefins and adhesives. Glide force testing passed at all intervals. The device met FDA expectations for combination product submission, and shelf life of 24 months was approved with the delivery system.

Checklist: Combination Product Stability Study Design

1. Define the complete drug-device configuration and intended use
2. Use ICH-aligned storage conditions and stability timepoints
3. Evaluate drug integrity in final assembled container
4. Conduct E&L studies and toxicological assessments
5. Perform mechanical function testing at each stability point
6. Verify container closure integrity and sterility
7. Align documentation with Pharma SOP and CTD Module 3

Common Mistakes to Avoid

• Testing the drug in bulk instead of in the final device configuration
• Overlooking mechanical or electronic device stability
• Delaying E&L testing until after design finalization
• Neglecting in-use simulation for products requiring dose withdrawal

Conclusion

Combination products demand an integrated stability strategy that accounts for drug quality, device reliability, and patient safety. By aligning biologic and engineering principles under a unified stability protocol, manufacturers can de-risk development and meet stringent global regulatory standards. For validated templates, integrated test plans, and regulatory-aligned SOPs, visit Stability Studies.

Addressing Stability Challenges in Biologic Combination Products

Biologic combination products—such as prefilled syringes, autoinjectors, dual-chamber cartridges, and drug-device systems—have transformed patient-centric care in biopharmaceuticals. While convenient and increasingly common, these complex formats pose unique stability challenges due to interactions between the biologic drug, device components, and packaging materials. This tutorial explores how to design robust stability strategies to address these challenges and meet regulatory expectations for combination products.

What Are Biologic Combination Products?

Combination products integrate a biologic drug with a device or delivery system. Common examples include:

• Prefilled syringes and pens
• Autoinjectors and on-body injectors
• Dual-chamber cartridges or reconstitution systems
• Co-formulated biologics in single containers

The interplay of drug, delivery system, and packaging materials requires careful evaluation of how stability is influenced throughout the product lifecycle.

Unique Stability Challenges in Biologic Combination Products

1. Drug-Device Interaction

Materials such as silicone oil (used for syringe lubrication), adhesives, or polymers may interact with the biologic and induce degradation, aggregation, or particulate formation.

2. Interface Stress

Interfaces such as stopper-barrel contact points or reconstitution systems are subject to shear, friction, and pressure—all of which can impact the protein’s structural integrity over time.

3. Temperature and Mechanical Stress

Wearable devices and autoinjectors may be exposed to real-world conditions like vibration, drops, and temperature cycles during storage and use. These require additional testing beyond standard ICH protocols.

4. Component Migration and Leachables

Extractables and leachables (E&L) from plastic components, adhesives, and lubricants can contaminate the formulation, especially over extended storage periods.

5. Dual Formulation Stability

Products that mix two biologics or a biologic and excipient just before administration must demonstrate individual and post-mixing stability.

Step-by-Step Guide to Stability Protocol Design

Step 1: Classify Product Type and Delivery System

Start by determining the category of combination product:

• Single biologic in prefilled syringe?
• Two-part dual chamber (lyophilized and diluent)?
• On-body wearable with heating or pump components?

This classification dictates what additional stress and compatibility testing is needed.

Step 2: Identify Materials in Contact with the Drug

Map out all materials in direct and indirect contact with the drug product, including:

• Syringe barrels (glass, COC)
• Elastomeric stoppers and plungers
• Coatings and lubricants (e.g., silicone, BPO-free coatings)
• Tubing, connectors, or valves in delivery systems

Perform risk assessments for extractables and leachables, adsorption, and chemical compatibility.

Step 3: Conduct Combination-Specific Stress Testing

Augment ICH Q5C protocols with tests specific to the combination format:

• Plunger glide force under storage conditions
• Silicone oil-induced aggregation tracking
• Mechanical shock and vibration stability (simulate drops and transit)
• On-body wear time simulation at 37°C

Ensure physical and chemical attributes (e.g., clarity, pH, potency) remain within specification throughout simulated use.

Step 4: Execute Extractables and Leachables (E&L) Studies

Per USP and FDA/EMA expectations, include:

• Controlled extraction using aggressive solvents
• Leachables testing under real-time and accelerated stability
• Toxicological risk assessments of detected species

Data must support both initial marketing authorization and post-approval changes in materials or suppliers.

Step 5: Monitor Functionality Over Shelf Life

Combination products must maintain delivery performance throughout their labeled shelf life. Include tests such as:

• Injection time consistency
• Force-to-actuate measurements
• Dose accuracy and completeness

These are critical for autoinjectors and on-body systems used in outpatient settings.

Step 6: Include Reconstituted Product Stability (If Applicable)

For dual-chamber systems or lyophilized products, conduct:

• In-use stability post-reconstitution (e.g., 6, 12, 24 hours)
• Compatibility with diluent and container materials
• Impact of reconstitution rate and method

Regulatory Framework for Combination Product Stability

Combination product guidance varies by region but commonly draws on:

• 21 CFR Part 4: USFDA rule on combination product CGMPs
• ICH Q8–Q10: Pharmaceutical development and risk management
• EMA Guideline on plastic materials and E&L studies
• ISO 11608 series: Needle-based injection systems

Document all findings in CTD Module 3 and your internal Pharma SOP system for lifecycle management.

Case Study: Autoinjector Protein Instability

A biosimilar manufacturer developing an autoinjector observed unexpected aggregation at 6 months. Investigation revealed interactions between protein and silicone oil from the syringe barrel. A change to baked-on silicone and addition of polysorbate 20 reduced aggregation by 80%, resolving the issue and allowing shelf life extension.

Checklist: Stability Testing in Combination Biologics

1. Classify product format (PFS, dual-chamber, wearable)
2. Identify and qualify all contact materials
3. Design ICH + mechanical + E&L + functionality studies
4. Test both physical and biological properties across use conditions
5. Document and trend changes in all system components

Common Mistakes to Avoid

• Relying solely on drug stability data—ignoring device impact
• Underestimating E&L risks from secondary components
• Skipping functionality testing during real-time studies
• Assuming syringe and vial stability profiles are interchangeable

Conclusion

Biologic combination products introduce additional complexity to stability testing, requiring holistic evaluation of container materials, device interfaces, and real-use conditions. By extending standard ICH protocols to incorporate mechanical, functional, and leachable-focused testing, developers can safeguard product integrity and ensure compliance across global regulatory pathways. For more in-depth guidance on biologic stability design, visit Stability Studies.